Vaxart (OTCMKTS:VXRT) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Shares of Vaxart, Inc. (OTCMKTS:VXRT) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.62 and traded as low as $0.4901. Vaxart shares last traded at $0.5025, with a volume of 238,924 shares traded.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Vaxart to a “hold” rating in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, Vaxart has a consensus rating of “Hold”.

Vaxart Price Performance

The company has a market cap of $121.35 million, a PE ratio of 3.12 and a beta of 1.10. The stock has a 50 day simple moving average of $0.54 and a two-hundred day simple moving average of $0.62.

Vaxart (OTCMKTS:VXRT) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06. The business had revenue of $27.18 million for the quarter, compared to analysts’ expectations of $26.21 million. Vaxart had a net margin of 15.88% and a return on equity of 53.04%. As a group, equities analysts anticipate that Vaxart, Inc. will post -0.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Vaxart

Several hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. purchased a new position in shares of Vaxart during the first quarter worth about $31,000. Creative Planning purchased a new position in shares of Vaxart in the 2nd quarter valued at approximately $33,000. Invesco Ltd. grew its stake in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares during the last quarter. Raymond James Financial Inc. increased its holdings in shares of Vaxart by 16.9% in the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 34,075 shares during the period. Finally, Jones Financial Companies Lllp increased its holdings in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 478,111 shares during the period. Institutional investors and hedge funds own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.